stock.name

Novo Nordisk - ADR

NVO

Market Cap$445.98B
Close$

Compare Novo Nordisk - ADR

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Novo Nordisk - ADRNovo Nordisk - ADR00.79%---
marketMarket Avg59.61.27%31%6.41
HealthcareHealthcare Avg62.31.27%15%7.30.9

Earnings Call Q4 2023

January 31, 2024 - AI Summary

Novo Nordisk reported strong performance in 2023, with double-digit sales and operating profit growth.
The company made progress on its strategic aspirations, including reaching more than 40 million patients without diabetes and obesity treatments and expanding the number of women in senior leadership positions.
Sales growth was driven by both North America operations (54% growth) and international operations (15% growth).

Exclusive for Stockcircle Pro members

Sign upSign Up
$133.35

Current Fair Value

4.1% upside

Undervalued by 4.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$445.98 Billion
Enterprise Value-
Dividend Yield$1.0256 (0.79%)
Earnings per Share$0.0
Beta0.67
Outstanding Shares3,435,128,000
Avg 30 Day Volume6,037,426

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio0.0
PEG-
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income-
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

ESG Score

No data

About Novo Nordisk

CEO: Lars Fruergaard Joergensen